EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieKlinische Studie (Phase III)

Nerandomilast in Patients with Progressive Pulmonary Fibrosis

Toby M Maher, Shervin Assassi, Arata Azuma, Vincent Cottin iD, Anna-Maria Hoffmann-Vold, Michael Kreuter, Justin M Oldham, Luca Richeldi, Claudia Valenzuela, Marlies S Wijsenbeek iD, Emmanuelle Clerisme-Beaty, Carl Coeck und 9 weitere

New England Journal of Medicine · 12.06.2025 · 392 (22) · 2203-2214

DOI: 10.1056/nejmoa2503643 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift New England Journal of Medicine, erschienen am 12.06.2025. Verfasst von Toby M Maher und 20 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pulmonary, Critical Care, and Sleep Medicine, Keck School of Medicine, University of Southern California, Los Angeles. Hauptthemen laut MEDLINE: Phosphodiesterase 4 Inhibitors, Pulmonary Fibrosis, Antifibrotic Agents, Immunomodulating Agents. Die Arbeit wurde bisher 241-mal zitiert (Crossref) und nennt 30 Literaturangaben. Gefördert von: The FIBRONEER-ILD trial was supported by Boehringer Ingelheim International GmbH..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Phosphodiesterase 4 InhibitorsPulmonary FibrosisAntifibrotic AgentsImmunomodulating AgentsAgedFemaleHumansMaleMiddle AgedDisease ProgressionDouble-Blind MethodLungTomography, X-Ray ComputedVital CapacityAdministration, OralDose-Response Relationship, DrugFollow-Up StudiesTreatment OutcomeCyclobutanesIndolesOrganic ChemicalsPiperidines

Substanzen

nintedanibPhosphodiesterase 4 InhibitorsBI 1015550Antifibrotic AgentsImmunomodulating AgentsCyclobutanesIndolesOrganic ChemicalsPiperidines

Autor:innen und Institutionen

  • Department of Pulmonary, Critical Care, and Sleep Medicine, Keck School of Medicine, University of Southern California, Los Angeles.
  • Section of Inflammation, Repair, and Development, National Heart and Lung Institute, Imperial College London, London.
  • Division of Rheumatology, McGovern Medical School, UTHealth Houston, Houston.
  • Clinical Research Center, Mihara General Hospital, Saitama, Japan.
  • Nippon Medical School, Tokyo.
  • National Reference Center for Rare Pulmonary Diseases, Louis Pradel Hospital, Hospices Civils de Lyon, Claude Bernard University Lyon 1, Unité Mixte de Recherche 754, European Reference Network for Rare Respiratory Dise…

ORCID-Profile: Vincent Cottin, Marlies S Wijsenbeek

Förderung

  • The FIBRONEER-ILD trial was supported by Boehringer Ingelheim International GmbH.

Zitieren

APA

Maher, T. M., Assassi, S., Azuma, A., Cottin, V., Hoffmann-Vold, A. M., Kreuter, M., Oldham, J. M., Richeldi, L., Valenzuela, C., Wijsenbeek, M. S., Clerisme-Beaty, E., Coeck, C., Gu, H., Ritter, I., Schlosser, A., Stowasser, S., Voss, F., Weimann, G., Zoz, D. F., …, & FIBRONEER-ILD Trial Investigators (2025). Nerandomilast in Patients with Progressive Pulmonary Fibrosis. New England Journal of Medicine, 392(22), 2203-2214. https://doi.org/10.1056/nejmoa2503643

Vancouver

Maher TM, Assassi S, Azuma A, Cottin V, Hoffmann-Vold AM, Kreuter M, et al. Nerandomilast in Patients with Progressive Pulmonary Fibrosis. New England Journal of Medicine. 2025;392(22):2203-2214. doi:10.1056/nejmoa2503643

BibTeX
@article{Maher2025,
  author = {Maher, Toby M and Assassi, Shervin and Azuma, Arata and Cottin, Vincent and Hoffmann-Vold, Anna-Maria and Kreuter, Michael and Oldham, Justin M and Richeldi, Luca and Valenzuela, Claudia and Wijsenbeek, Marlies S and Clerisme-Beaty, Emmanuelle and Coeck, Carl and Gu, Hui and Ritter, Ivana and Schlosser, Arno and Stowasser, Susanne and Voss, Florian and Weimann, Gerrit and Zoz, Donald F and Martinez, Fernando J and FIBRONEER-ILD Trial Investigators, FIBRONEER-ILD Trial Investigators},
  title = {Nerandomilast in Patients with Progressive Pulmonary Fibrosis},
  journal = {New England Journal of Medicine},
  year = {2025},
  volume = {392},
  number = {22},
  pages = {2203--2214},
  doi = {10.1056/nejmoa2503643}
}
Kostenlos starten →